Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 5/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.44 |
| ▸ | AHR | P35869 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | CMA1 | P23946 | 1/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | BCL6 | P41182 | 1/20 | 0.39 |
| ▸ | PGK1 | P00558 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6743543 | 0.81 | CRBN (0.51) | SMYD3CRBNAHRGAACMA1 | |
| SCHEMBL152807 | 0.79 | HDAC3 (0.45) | SMYD3CRBNAHRCMA1POLB | |
| SCHEMBL5441646 | 0.75 | AHR (0.60) | SMYD3AHRGAACMA1PDE3B | |
| SCHEMBL3662896 | 0.73 | CRBN (0.52) | SMYD3CRBNAHRCMA1POLB | |
| SCHEMBL154971 | 0.73 | SMYD3 (0.60) | SMYD3CRBNAHRPOLB | |
| SCHEMBL17120924 | 0.73 | AHR (0.53) | SMYD3AHRGAACMA1PDE3B | |
| SCHEMBL2720180 | 0.72 | SMYD3 (0.56) | SMYD3AHRGAACMA1 | |
| SCHEMBL29779539 | 0.72 | SMYD3 (0.56) | SMYD3AHRGAACMA1 | |
| SCHEMBL30951184 | 0.71 | PGK1 (0.48) | ROCK2ALDH1A1POLBPGK1CA1 | |
| SCHEMBL3827983 | 0.71 | PGK1 (0.48) | ROCK2ALDH1A1POLBPGK1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050090498-A1 | 3-Quinolin-2(1h)-ylideneindolin-2-one derivative | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2005-04-28 | — | — | US | disclosed |
| EP-1396490-A1 | 3-QUINOLINE-2-(1H)-YLIDENEINDOLIN-2-ONE DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2004-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090498-A1 | 3-Quinolin-2(1h)-ylideneindolin-2-one derivative | KDR, FLT4, FLT1 | SMYD3 4119/4885CRBN 3205/4885AHR 4782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.